On February 10, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara BioCapital, Coastlands Capital, Eventide Asset Management, Perceptive Advisors, RA Capital Management, ADAR1 Capital Management, Affinity Asset Advisors and Acuta Capital Partners.

Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering.

Sutro intends to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, primarily for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to the Company, capital expenditures and other general corporate purposes.

The securities are being offered by Sutro pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, may also be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at [email protected] Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at View Source

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Sutro, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Sutro Biopharma, FEB 10, 2026, View Source [SID1234662574])

On February 10, 2026 Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and CNS-related diseases, reported an update on key development progress achieved during 2025 and outlined its strategic direction as the Company enters 2026 with continued momentum across its pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025: Continued Execution Across a Late-Stage, Diversified Pipeline

Oncotelic transitioned from platform build-out to execution and validation, advancing AI-driven discovery (PDAOAI), moving key assets into the clinic, publishing high-impact translational science, and reinforcing asset value through independent validation. Collectively, these milestones establish a strong foundation for late-stage development, partnering, and strategic financing.

Oncotelic Therapeutics – 2025 Key Accomplishments

1. Platform Innovation & AI Enablement (PDAOAI)

In 2025, Oncotelic formally unveiled PDAOAI, its proprietary AI-enabled knowledge platform built on a comprehensive TGF-β-centric corpus. The platform was expanded to support interactive querying, biomarker discovery, and translational hypothesis generation, and was publicly introduced alongside peer-reviewed GBM and pancreatic cancer research. PDAOAI now functions as a cross-program decision-support layer integrating molecular biology, clinical outcomes, and regulatory-grade literature.

2. Clinical Progress & First-in-Human Readiness

Oncotelic achieved multiple clinical milestones across its pipeline. The company successfully completed a Phase 1 clinical trial of OT-101 in combination with IL-2. In parallel, its IV everolimus Deciparticle program (Sapu-003) advanced from preclinical development into first-in-human clinical testing.

3. Deciparticle Platform Validation (Sapu-003)

Throughout 2025, Oncotelic released a coordinated body of data validating the Deciparticle platform:

Demonstrated broad applicability across hydrophobic small-molecule drug classes
Reported favorable PK and tissue-distribution profiles, including reduced gastrointestinal accumulation compared with oral everolimus
Introduced a biomarker-guided framework to identify patient populations most likely to benefit from IV mTOR inhibition
These results position Deciparticle as a differentiated delivery technology for oncology and other systemic indications.

4. Peer-Reviewed Science & Biomarker Leadership

Oncotelic and collaborators published multiple peer-reviewed studies in 2025, reinforcing the company’s leadership in TGFB2-centric biology. Key publications linked TGFB2 expression and methylation status to survival outcomes in pancreatic cancer, glioblastoma, and liver cancer, including age- and context-dependent effects. Additional work reviewed sub-20 nm nanoparticle design principles, supporting the scientific rationale behind the Deciparticle platform.

5. Strategic Partnerships & Global Development Infrastructure

The company entered a strategic partnership with Medicilon to access rapid IND-enabling capabilities. These capabilities complement Oncotelic’s global regulatory strategy.

6. Corporate Development, Valuation & Visibility

In 2025, an independent third-party analysis valued the GMP Bio joint-venture pipeline at approximately $1.7 billion, materially strengthening Oncotelic’s asset-level valuation narrative. The company increased capital-markets visibility through various investor presentations, while continuing disciplined communication around pipeline maturation and platform leverage.

Looking Ahead to 2026: Sustained Momentum, Strategic Execution, and Value Recognition

As the Company enters 2026, Oncotelic plans to build on the progress achieved in 2025 with an emphasis on continued development momentum, thoughtful capital allocation, strategic execution, and increased financial transparency. The Company’s forward priorities include:

Advancing clinical programs toward their next inflection points
Further evaluating regulatory and development pathways across oncology and CNS indications
Exploring partnership, licensing, and collaboration opportunities aligned with its late-stage assets
Continuing to strengthen operational readiness to support future growth initiatives
Completing a second independent U.S.-based valuation to support the remeasurement of its 45% equity interest in the GMP Bio joint venture, with the resulting valuation expected to be reflected on the Company’s balance sheet upon completion, subject to applicable accounting standards

Oncotelic believes its steady progress in 2025 has positioned the Company with a clear development trajectory, enhanced asset visibility, and multiple opportunities to unlock long-term value.

(Press release, Oncotelic, FEB 10, 2026, View Source [SID1234662575])

On February 10, 2026 AstraZeneca reported full year and Q4 2025 results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, AstraZeneca, FEB 10, 2026, View Source [SID1234662554])

On February 10, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, reported that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

More information about the summit is available at: https://glioblastoma-drugdevelopment.com.

Lantern’s proprietary AI and machine learning platform, RADR, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, including recurrent glioblastoma and pediatric brain tumors such as atypical teratoid/rhabdoid tumors (ATRT)—for which STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation.

In his presentation on Day Two (Thursday, February 19, 2026, at 10:30 a.m. ET), Mr. Sharma will highlight how Lantern applied RADR to:

Elucidate the mechanism of action of STAR-001
Identify patient biomarkers to inform clinical use
Select optimal cancer indications
Discover novel combination therapies in neuro-oncology
The talk will emphasize AI-driven insights and approaches that are helping overcome challenges in treating aggressive brain cancers like glioblastoma and ATRT.

(Press release, Lantern Pharma, FEB 10, 2026, View Source [SID1234662576])

On February 10, 2026 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai") and Araris Biotech AG (hereafter "Araris") reported that Chugai has exercised its option under the Research Collaboration and Option to License Agreement ("RCO") previously announced by Araris in 2025. The exercised option grants Chugai a license to Araris’ proprietary AraLinQ linker-payload platform for the generation of novel ADCs against one target selected by Chugai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Araris’ innovative AraLinQ technology is expected to deliver therapeutic effects in a tumor-selective manner by efficiently conjugating multiple anticancer payloads to a single antibody. By combining this technology with our core strength in antibody engineering, we aim to create innovative cancer therapeutics with enhanced efficacy and safety," said Dr. Osamu Okuda, President and CEO of Chugai.

"We are very pleased that Chugai has elected to exercise its option to license our AraLinQ technology for the development of next-generation ADCs with enhanced efficacy and tolerability. We are proud of the scientific progress achieved through this collaboration to date and look forward to seeing this program advance toward the clinic" said Dr. Dragan Grabulovski, CEO of Araris.

Dr. Filippo Mulinacci, CBO of Araris, stated: "Chugai’s decision to license AraLinQ technology represents a significant milestone for Araris. It further validates the scientific progress achieved by our team and reinforces Araris’ positioning as a partner of choice for the development of highly differentiated, multi-payload ADCs with antibody-like pharmacokinetics and exceptional linker stability."

With the exercise of the option, Araris will receive an immediate upfront payment and may receive additional milestone payments and royalties on potential commercial sales. The overall RCO provides for a total potential consideration of approximately up to USD 780 million, subject to the exercise of all options and achievement of certain milestones.

(Press release, Chugai, FEB 10, 2026, View Source [SID1234662560])